Please note. Mixed status: not FDA-approved in the US. Approved outside the US: Canada (Duratocin). Information is for clinical awareness only. Not a recommendation to use.
No perspectives yet — be the first!
Be the first verified clinician to share a view on Carbetocin.
100% anonymous · NPI-verifiedFDA status last checked Nov 11, 2026
A long-acting synthetic agonist analogue of human oxytocin, with antihemorrhagic and uterotonic activities. Upon administration, carbetocin targets, binds to and activates peripheral oxytocin receptors that are present on the smooth musculature of the uterus.
Carbetocin
Not approved by the FDA, but approved in Canada.
Tested in at least one proper controlled study in people, with results.
There is no FDA-approved product with this peptide.
Approved by these regulators outside the US. Not approved by the FDA.
How it works. Proven facts and ideas still being studied are kept apart.
Not yet reviewed.
Tested in at least one proper controlled study in people, with results.
Not FDA-approved in the US. Approved and marketed in Canada as Duratocin (Health Canada DIN 02496526).
Last verified: Nov 11, 2026
Share your pre-launch perspective on Carbetocin and help peers make informed prescribing decisions.
Your 45-second perspective helps thousands of colleagues.
Your real-world insights guide colleagues
Your identity stays private — only specialty/region shown
Compare your perspective to specialty peers
